AVNR Key Stats
- Avanir Pharmaceuticals to Participate in Two Upcoming Investor Conferences PR Newswire May 22
- July Options Now Available For Avanir Pharmaceuticals (AVNR) May 20
- AVANIR PHARMACEUTICALS, INC. Financials May 17
- Nasdaq stocks posting largest volume increases May 15
- Investors Ride 5 Healthcare Earnings Rollercoaster Rides May 12
- Avanir Pharmaceuticals Increases Sales but Misses Estimates on Earnings May 10
- Avanir Pharmaceuticals Increases Sales but Misses Estimates on Earnings Fool May 9
- Avanir Reports Strong Revenue but Misses on Earnings May 9
- Wider-than-Expected Loss at Avanir May 9
- Wider-than-Expected Loss at Avanir - Analyst Blog Zacks May 9
AVNR Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). AVANIR Pharmaceuticals is up 19.78% over the last year vs S&P 500 Total Return up 28.07%, Catalyst Pharmaceutical Partners up 0.24%, and Pernix Therapeutics down 49.01%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Income Statement View Statement
Pro Ratings for AVNR
Pro Report PDF for AVNR
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download AVNR Pro Report PDF
Pro Strategies Featuring AVNR
Did AVANIR Pharmaceuticals make it into our Pro Portfolio Strategies?